Clintrial s.r.o.
- Address
- lock Available on a paid plan
Clintrial s.r.o. - Dermatology and Neuroscience Research Center
Clintrial s.r.o. is a specialized clinical research facility with extensive expertise in dermatological conditions and neuropsychiatric disorders. The center demonstrates particular strength in conducting complex Phase II and Phase III trials, with a pronounced focus on inflammatory skin diseases and cognitive disorders. Their research portfolio reflects a commitment to advancing therapeutic options for patients with chronic, difficult-to-treat conditions.
- Atopic Dermatitis: Multiple trials investigating novel biologics, biosimilars, and conventional therapeutics including ANB032, LEO 138559, BMS-986326, amlitelimab, and methotrexate
- Cognitive and Psychiatric Disorders: Research in schizophrenia-associated cognitive impairment, Alzheimer's disease, and adjunctive treatments for treatment-resistant schizophrenia
- Autoimmune and Inflammatory Conditions: Studies in plaque psoriasis, rheumatoid arthritis, and migraine prevention
The center's dermatology program is particularly robust, with extensive experience evaluating biologic therapies and biosimilar agents across varying severity levels of atopic dermatitis. In neuroscience, Clintrial s.r.o. conducts sophisticated trials addressing cognitive impairment in schizophrenia and mild cognitive impairment due to Alzheimer's disease, demonstrating capability in complex neuropsychological assessments. Their diverse therapeutic portfolio includes comparative effectiveness studies, such as the TEMPLE trial comparing migraine preventive treatments, showcasing their expertise in real-world tolerability and safety assessments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 59 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 55 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1Intra-Cellular Therapies Inc.3active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clintrial s.r.o.
lock Showing 1 of 72 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis | Dice Therapeutics Inc. | Phase II | Not Recruiting | Aug 2023 | Mar 2024 |
IMP list
lock Showing 1 of 59 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 5 | Unknown | 2024-05-07 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.